Skip to main content
. 2013 Sep;5(Suppl 4):S397–S406. doi: 10.3978/j.issn.2072-1439.2013.08.08

Table 2. High lightened studies of targeted treatment and possible biomarkers of malignant pleural mesothelioma.

First name, year, ref Phase/
study
n Chemotherapy regimens Targeted treatment/biomarker investigated Response rates (RR) Median progression-free survival (PFS) months Median overall survival (OS) months Outcome
Gregorc, 2010 (81) II 57 Pemetrexed Human tumor necrosis factor alpha 44-46% 2.8 12.1 Warrant additional evaluation
Kindler, 2012 (80) II 108 Gemcitabine/Cisplatin Bevacizumab 24.5% 6.9 15.6 Addition of bevacizumab did not significantly improve PFS or OS
Nowak, 2013 (82) II 30 Pemetrexed/Platinum Vascular Disrupting Agent BNC105P 43% 1.5 8.2 Insufficient
O’Brien, 2013 (83) II 82 Cisplatin and bortezomib - 28.4% 5.1 13.5 PFS rate at 18 weeks as strong predictor of survival